AR063643A1 - Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas - Google Patents
Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticasInfo
- Publication number
- AR063643A1 AR063643A1 ARP070105009A ARP070105009A AR063643A1 AR 063643 A1 AR063643 A1 AR 063643A1 AR P070105009 A ARP070105009 A AR P070105009A AR P070105009 A ARP070105009 A AR P070105009A AR 063643 A1 AR063643 A1 AR 063643A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- carbamoyl
- carbon
- sulfamoyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 26
- -1 nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, mercapto, sulfamoyl Chemical group 0.000 abstract 23
- 229910052757 nitrogen Inorganic materials 0.000 abstract 17
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 8
- 229910052799 carbon Chemical group 0.000 abstract 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos químicos de fórmula (1) o sales de éstos aceptables para el uso farmacéutico, que poseen actividad de inhibición de la quinasa CSF-1R, por lo que son útiles en virtud de su actividad anti-cáncer, y por lo tanto, en métodos para el tratamiento del cuerpo humano o de los animales La solicitud también se relaciona con procesos para la fabricación de dichos compuestos químicos, con composiciones farmacéuticas que los contienen, y con su uso en la fabricación de medicamentos para usar en la producción de un efecto anti-cáncer en un animal de sangre caliente, tal como el hombre. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1) en donde: uno de R1 y R2 se selecciona entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, carbociclilo o heterociclilo unido a carbono; en donde este R1 o R2 puede estar sustituido opcionalmente en un carbono por uno o más R5, y en donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R6, y el otro R1 o R2 se selecciona entre hidrógeno, halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aIcoxi C1- 6, aIcanoiIo C1-6, alcanoiloxi C1-6, N-(C1-6alquil)amino, N,N(C 1-6 alquiI)2amino, N-(C1-6 alquiI)-N-(C1-6 alcoxi)amino, alcanoilamino C1-6, alcoxicarbonilo C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquil)2sulfamoilo, alquilsulfonilamino C1-6, carbociclilo o heterociclilo unido a carbono, en donde este R1 o R2 puede estar sustituido opcionalmente en un carbono por uno o más R7, y en donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R8; R3 es hidrógeno, o halo; R4 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aIcoxi C1-6, aIcanoiIo C1-6, alcanoiloxi C1-6, N-(C1-6alquil)amino, N,N(C1-6 alquiI)2amino, N-(C1-6 alquiI)-N-(C1-6 alcoxi)amino, alcanoilamino C1-6, N-(C1-6 alquil)carbamoilo, N,N-(C1-6 alquil)2carbamoilo, alquil C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquil)2sulfamoilo, alquilsulfonilamino C1-6, carbociclilo o heterociclilo en donde R4 puede estar sustituido opcionalmente en un carbono por uno o más R9, y en donde si dicho heterociclilo contiene una porción - NH- ese nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R10, o en donde si dos grupos R4 están sobre carbonos adyacentes, pueden formar opcionalmente un anillo carbocíclico o un anillo heterocíclico; en donde dicho anillo carbocíclico o anillo heterocíclico puede estar sustituido opcionalmente en un carbono por uno o más R11; y en donde si dicho anillo heterocíclico contiene una porción -NH- ese nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R12; n es 0-3; en donde los valores de R4 son iguales o diferentes; R5, R7, R9 y R11 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, aIcoxi C1-6, aIcanoiIo C1-6, alcanoiloxi C1-6, N-(C1-6alquil)amino, N,N(C1-6 alquiI)2amino, N-(C1-6 alquiI)-N-(C1-6 alcoxi)amino, alcanoilamino C1-6, N-(C1-6 alquil)carbamoilo, N,N-(C1-6 alquil)2carbamoilo, alquil C1-6S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-6, alcoxicarbonilamino C1-6, N-(C1-6 alquil)sulfamoilo, N,N-(C1-6 alquil)2sulfamoilo, alquilsulfonilamino C1-6, carbociclil-R13- o heterociclil-R14-; en donde R5, R7, R9 y R11 en forma independiente entre sí pueden estar sustituidos opcionalmente en un carbono por uno o más R15; y en donde si dicho heterociclilo contiene una porción -NH- ese nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R16; R13 y R14 se seleccionan en forma independiente entre un enlace directo. -O-. -N(R17)-, -C(O)-, -N(R18)C(O)-, -C(O)N(R19)-, -S(O)s-, -SO2N(R20)- o -N(R21)SO2-; en donde R17, R18, R19, R20 y R21se seleccionan en forma independiente entre hidrógeno o alquilo C1-6 y s es 0-2, R6, R8, R10, R12 y R16 se seleccionan en forma independiente entre alquilo C1-6, aIcanoiIo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoilo, N (C1-6 alquil)carbamoilo, N,N-(C1-6 alquil)carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; en donde R6, R8, R10, R12 y R16 en forma independiente entre sí pueden estar sustituidos opcionalmente en un carbono por uno o más R22; y R15 y R22 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N- metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, fenilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N- etilsulfamoilo, N,N-dimetilsulfamoilo, N,N-dietilsulfamoilo o N-metil-N-etilsulfamoilo, o una sal aceptable para uso farmacéutico del mismo: con la salvedad de que si R1 es fenilo o pirid-4-ilo, R2 no es hidrógeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86524506P | 2006-11-10 | 2006-11-10 | |
| US91618207P | 2007-05-04 | 2007-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063643A1 true AR063643A1 (es) | 2009-02-04 |
Family
ID=38969976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105009A AR063643A1 (es) | 2006-11-10 | 2007-11-09 | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090270450A1 (es) |
| EP (1) | EP2084134A1 (es) |
| JP (1) | JP2010509300A (es) |
| KR (1) | KR20090077003A (es) |
| AR (1) | AR063643A1 (es) |
| AU (1) | AU2007319059A1 (es) |
| BR (1) | BRPI0718721A2 (es) |
| CA (1) | CA2669034A1 (es) |
| CO (1) | CO6220939A2 (es) |
| EC (1) | ECSP099322A (es) |
| IL (1) | IL198671A0 (es) |
| MX (1) | MX2009004908A (es) |
| NO (1) | NO20091683L (es) |
| PE (1) | PE20081393A1 (es) |
| RU (1) | RU2009121816A (es) |
| TW (1) | TW200829555A (es) |
| WO (1) | WO2008056148A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
| US20110190272A1 (en) * | 2008-05-07 | 2011-08-04 | Astrazeneca Ab | Chemical compounds |
| EP2445886B1 (en) | 2009-06-25 | 2016-03-30 | Amgen, Inc | 4-aminoquinoline derivatives as pi3k inhibitors |
| CA2806332C (en) * | 2010-07-30 | 2017-11-14 | Oncotherapy Science, Inc. | Quinoline derivatives and melk inhibitors containing the same |
| EP2635279A4 (en) * | 2010-11-05 | 2014-10-29 | Glaxosmithkline Ip No 2 Ltd | CHEMICAL COMPOUNDS |
| WO2012116137A2 (en) * | 2011-02-24 | 2012-08-30 | Emory University | Jab1 blocking compositions for ossification and methods related thereto |
| ES2609578T3 (es) | 2011-03-04 | 2017-04-21 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| AU2014219024B2 (en) | 2013-02-20 | 2018-04-05 | KALA BIO, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| AR094707A1 (es) | 2013-02-21 | 2015-08-19 | Glaxosmithkline Ip Dev Ltd | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2019084271A1 (en) | 2017-10-25 | 2019-05-02 | Children's Medical Center Corporation | PAPD5 INHIBITORS AND METHODS OF USE |
| WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CA3137768A1 (en) | 2019-04-24 | 2020-10-29 | Children's Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8621425D0 (en) * | 1986-09-05 | 1986-10-15 | Smith Kline French Lab | Compounds |
| DK273689A (da) * | 1988-06-06 | 1989-12-07 | Sanofi Sa | 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler |
| EP0480052B1 (en) * | 1990-03-28 | 1998-01-14 | Otsuka Pharmaceutical Co., Ltd. | Quinoline derivative, antiulcer drug containing the same, and production of said derivative |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| ES2457396T3 (es) * | 1998-09-29 | 2014-04-25 | Wyeth Holdings Llc | 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas |
| US6521618B2 (en) * | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
| SE0101675D0 (sv) * | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| TWI328009B (en) * | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0322726D0 (en) * | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| US7479561B2 (en) * | 2004-08-16 | 2009-01-20 | Wyeth | 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors |
| BRPI0516995A (pt) * | 2004-10-22 | 2008-09-30 | Wyeth Corp | composto que tem a estrutura |
| US20060264439A1 (en) * | 2005-05-17 | 2006-11-23 | Supergen, Inc. | Inhibitors of polo-like kinase-1 |
| PL2010496T3 (pl) * | 2006-04-14 | 2011-01-31 | Astrazeneca Ab | 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R |
| CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
-
2007
- 2007-11-07 TW TW096142111A patent/TW200829555A/zh unknown
- 2007-11-08 MX MX2009004908A patent/MX2009004908A/es not_active Application Discontinuation
- 2007-11-08 RU RU2009121816/04A patent/RU2009121816A/ru not_active Application Discontinuation
- 2007-11-08 WO PCT/GB2007/004263 patent/WO2008056148A1/en not_active Ceased
- 2007-11-08 BR BRPI0718721-1A patent/BRPI0718721A2/pt not_active IP Right Cessation
- 2007-11-08 KR KR1020097011100A patent/KR20090077003A/ko not_active Withdrawn
- 2007-11-08 EP EP07824496A patent/EP2084134A1/en not_active Withdrawn
- 2007-11-08 JP JP2009535798A patent/JP2010509300A/ja active Pending
- 2007-11-08 AU AU2007319059A patent/AU2007319059A1/en not_active Abandoned
- 2007-11-08 CA CA002669034A patent/CA2669034A1/en not_active Abandoned
- 2007-11-09 PE PE2007001549A patent/PE20081393A1/es not_active Application Discontinuation
- 2007-11-09 AR ARP070105009A patent/AR063643A1/es not_active Application Discontinuation
-
2009
- 2009-04-28 NO NO20091683A patent/NO20091683L/no not_active Application Discontinuation
- 2009-05-05 US US12/435,856 patent/US20090270450A1/en not_active Abandoned
- 2009-05-08 CO CO09046886A patent/CO6220939A2/es not_active Application Discontinuation
- 2009-05-10 IL IL198671A patent/IL198671A0/en unknown
- 2009-05-12 EC EC2009009322A patent/ECSP099322A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2669034A1 (en) | 2008-05-15 |
| AU2007319059A1 (en) | 2008-05-15 |
| JP2010509300A (ja) | 2010-03-25 |
| RU2009121816A (ru) | 2010-12-20 |
| NO20091683L (no) | 2009-05-27 |
| TW200829555A (en) | 2008-07-16 |
| US20090270450A1 (en) | 2009-10-29 |
| ECSP099322A (es) | 2009-06-30 |
| EP2084134A1 (en) | 2009-08-05 |
| CO6220939A2 (es) | 2010-11-19 |
| BRPI0718721A2 (pt) | 2013-12-03 |
| IL198671A0 (en) | 2010-02-17 |
| KR20090077003A (ko) | 2009-07-13 |
| PE20081393A1 (es) | 2008-11-26 |
| MX2009004908A (es) | 2009-05-19 |
| WO2008056148A1 (en) | 2008-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
| AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
| AR053683A1 (es) | Derivados de piperidina con actividad antibacteriana | |
| AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
| AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
| AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
| AR047702A1 (es) | Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular | |
| AR055249A1 (es) | Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas | |
| AR041594A1 (es) | Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1 | |
| AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
| AR052170A1 (es) | Derivados de pirimidina utiles por su actividad anti-proliferacion celular | |
| AR062406A1 (es) | Derivados de quinazolina como inhibidores de b-raf | |
| AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR040408A1 (es) | Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
| AR056210A1 (es) | 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa | |
| AR039257A1 (es) | Derivados de benzamida | |
| AR064208A1 (es) | Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas. | |
| AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
| AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
| AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
| AR040409A1 (es) | Inhibidores de histona desacetilasa | |
| AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
| AR061118A1 (es) | Derivados de pirimidina, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de cdk2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |